VANIA HOOD: Open Payments
NPI 1043833163 · LA JOLLA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$940 in 55 payments from 9 companies in 2025. Trend: 2023 $701 · 2024 $1,204 · 2025 $940
Food & beverage: $940
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. | 16 | $191 |
| Gilead Sciences, Inc. | 11 | $185 |
| Novo Nordisk Inc | 4 | $176 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 15 | $173 |
| GlaxoSmithKline, LLC. | 3 | $73 |
| Hologic Sales and Service, LLC | 3 | $70 |
| ViiV Healthcare Company | 1 | $29 |
| Exeltis, USA Inc. | 1 | $25 |
| ABBVIE INC. | 1 | $19 |
Products named: INJECTAFER, XIFAXAN, Ozempic, APTIMA, TRELEGY ELLIPTA, APRETUDE, Rybelsus, SLYND.
Industry payments across CA — which companies pay providers there.
